Antibodies against c3a receptor
CA 2492457 A1 · Owner: Human Genome Sciences, Inc. · Inventors: Rosen, Craig A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to antibodies and related molecules that specifically bind to C3a Receptor. Such antibodies have uses for example, in , the prevention and treatment of asthma allergy, and other related , inflammatory and immune disorders. The invention also relates to nucleic acid molecules encoding anti-C3a Receptor antibodies vectors and host cells , containing these nucleic acids and methods for producing the same. The present invention relates to methods and compositions for preventing detecting, diagnosing, treating or ameliorating a disease or disorder especially inflammatory and other related disorders comprising administering , to an animal preferably a human, an …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.